BioSpace News Archive

Drug Development

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

Can-Fite BioPharma Ltd today announced that Alimentary Pharmacology & Therapeutics published an article titled “ Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis” authored by Can-Fite’s CEO Dr. Pnina Fishman.

October 21, 2021
·
6 min read
Business

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

IQVIA Holdings Inc. today reported financial results for the quarter ended September 30, 2021.

October 21, 2021
·
20 min read
Myoclonus Drugs Market is Projected to Garner Significant Revenues by 2025

Myoclonus is a symptom rather than a disease. It is described as involuntary jerking of a muscle. It is caused by sudden muscle contractions known as positive myoclonus.

October 21, 2021
·
6 min read
Orthopedic Contract Manufacturing Market: Increase in Number of Sports Injuries to drive the market

The orthopedic industry has seen a significant reduction in new product development and approvals in the past few years due to the global financial crisis.

October 21, 2021
·
5 min read
Policy

Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma

Ultimovacs ASA announced its universal cancer vaccine, UV1, in combination with checkpoint inhibitors has received Fast Track designation from the U.S. FDA in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab.

October 21, 2021
·
4 min read
Business

Alligator Bioscience AB: Interim report January-September 2021

“We continued to make great strides in the third quarter of 2021. The first patient was dosed in OPTIMIZE-1, our clinical Phase II study, that will assess the effect of mitazalimab in first line pancreatic cancer.

October 21, 2021
·
4 min read
Business

Atreca Enters into Licensing Agreement with Bill & Melinda Gates Medical Research Institute to Develop a Monoclonal Antibody for the Prevention of Malaria

Atreca, Inc. today announced that it has entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute (the “Institute” or “Gates MRI”) to develop MAM01/ATRC-501, a novel monoclonal antibody entering preclinical development, for the prevention of malaria.

October 21, 2021
·
5 min read
Business

Zogenix to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4

Zogenix today announced data that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, November 4, 2021, at 4:30 PM Eastern Time.

October 21, 2021
·
1 min read
Biotech Bay

Adagene to Participate in the Jefferies Virtual China Biotech Summit

Adagene Inc. today announced that Adagene’s Co-founder, Chief Executive Officer and Chairman, Peter Luo, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual China Biotech Summit to be held October 26, 2021.

October 21, 2021
·
1 min read